| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55d34cf2dd4eaa9974ebc126e36c39bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b88ea322da9528a9c39dc66cf0dec21d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f01cf5dca63cc74ebace2f17a5b5a73c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9fd277a9a9d92f14a522f2d76c7c3a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e107d292d22b1c35cedd9f5c4ba9d19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 |
| filingDate |
2017-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea79a5a9bb3e64443872888efc4e7800
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d7584cc807c985db5d2e05373e2d362
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d572c16eade91a869aabb20e8279ac4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b944144debeee664afdd61946be6293 |
| publicationDate |
2017-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017192483-A1 |
| titleOfInvention |
Monoclonal antibody cocktail for treatment of ebola infections |
| abstract |
Antibody variants originating from the monoclonal antibody 13C6, and wherein the N-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind Ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with Ebola virus when used in combination with one or more additional anti-Ebola mAbs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the Ebola virus. |
| priorityDate |
2016-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |